WY-14643 (Pirinixic Acid): Selective PPARα Agonist for Metabolic Research and Inflammation Modulation

Executive Summary: WY-14643 (Pirinixic Acid) is a highly selective PPARα agonist with an IC50 of 10.11 μM for human PPARα, enabling precise modulation of lipid metabolism and inflammatory pathways in both cellular and animal models (APExBIO). Aliphatic α-substitution enhances its dual PPARα/γ agonism, broadening its application in metabolic research. In vivo, WY-14643 improves insulin sensitivity, reduces plasma glucose and triglyceride levels, and lowers hepatic fat content in high fat-fed rats. It increases hepatic TNFα mRNA via Kupffer cells, indirectly stimulating hepatocyte mitogenesis (Wang et al., HEP-21-0169). Its robust and reproducible effects have positioned it as a benchmark compound for translational research in liver regeneration and metabolic disorders.

Biological Rationale

Peroxisome proliferator-activated receptor alpha (PPARα) is a nuclear receptor that regulates genes involved in lipid metabolism, inflammation, and energy homeostasis (WY-14643: Selective PPARα Agonist for Metabolic Research ...). Selective activation of PPARα is critical for research into non-alcoholic fatty liver disease, type 2 diabetes, atherogenesis, and liver regeneration. WY-14643, offered by APExBIO, is a structurally defined, highly selective PPARα agonist that provides robust, reproducible results across in vitro and in vivo systems (product page). Its dual activity, upon α-substitution, further enables investigation into PPARγ-related pathways, supporting studies in adipogenesis and inflammation (Driving Innovation in PPAR Signaling). This article extends prior work by integrating recent mechanistic evidence for YAP-TEAD involvement in PPARα-driven liver regeneration, as established in recent murine models (Wang et al., HEP-21-0169).

Mechanism of Action of WY-14643 (Pirinixic Acid)

WY-14643 binds selectively to PPARα, functioning as a potent transcriptional activator. Its IC50 for human PPARα is 10.11 μM, establishing its high affinity and selectivity (APExBIO). Upon ligand binding, PPARα forms a heterodimer with retinoid X receptor (RXR), then binds to peroxisome proliferator response elements (PPREs) in DNA, upregulating genes controlling fatty acid β-oxidation, lipoprotein metabolism, and anti-inflammatory processes. Aliphatic α-substitution on the WY-14643 scaffold increases its PPARγ activity, creating balanced dual agonists active in the low micromolar range.
In vivo, activation of PPARα by WY-14643 upregulates hepatic genes responsible for fatty acid catabolism and stimulates hepatocyte mitogenesis, partly through increased TNFα mRNA expression in Kupffer cells. This effect is YAP-TEAD dependent, as demonstrated by genetic and pharmacologic inhibition experiments in mouse models (Wang et al., HEP-21-0169). In endothelial cells, WY-14643 reduces TNF-α-induced vascular cell adhesion molecule-1 (VCAM-1) expression and monocyte adhesion, indicating marked anti-inflammatory potential.

Evidence & Benchmarks

• WY-14643 demonstrates an IC50 of 10.11 μM for human PPARα, confirming high selectivity and potency (APExBIO).
• α-substituted WY-14643 analogs exhibit dual PPARα/γ agonism in the low micromolar range, expanding applications in metabolic and inflammatory research (Dossier Update).
• In high fat-fed rats, oral WY-14643 (3 mg/kg/day, 2 weeks) significantly lowers plasma glucose, triglycerides, leptin, and muscle triglyceride content, and enhances insulin sensitivity without weight gain (APExBIO).
• WY-14643 upregulates hepatic TNFα mRNA via Kupffer cells, indirectly promoting hepatocyte mitogenesis, as shown in murine PHx models (Wang et al., HEP-21-0169, Capital Medical University).
• Pretreatment with 250 μM WY-14643 in endothelial cells down-regulates TNF-α-induced VCAM-1 and reduces monocyte adhesion, demonstrating anti-inflammatory effects (Unlocking PPARα Signaling).
• YAP-TEAD signaling is required for PPARα-driven liver regeneration post-hepatectomy, evidenced by genetic and pharmacologic inhibition studies in mice (Wang et al., HEP-21-0169, Supporting Material and Methods).

Applications, Limits & Misconceptions

WY-14643 is a versatile tool for dissecting PPARα and, upon modification, PPARγ pathways in metabolic disease, inflammation, and liver regeneration research. It is optimally used in preclinical models, including cell culture and rodent systems. Recent studies clarify its role in promoting hepatocyte proliferation through YAP-TEAD mediation, extending beyond classic lipid metabolism paradigms. This article clarifies and updates earlier coverage (Unleashing the Next Frontier) by providing explicit evidence for YAP-TEAD interactions and direct metabolic benchmarks.

Common Pitfalls or Misconceptions

• WY-14643 is not active in the absence of PPARα; loss-of-function models confirm its effects are PPARα-dependent.
• Clinical or diagnostic use is not supported; it is strictly for scientific research applications (APExBIO).
• Water insolubility requires dissolution in DMSO or ethanol, with recommended concentrations ≥16.2 mg/mL (DMSO) or ≥48.8 mg/mL (ethanol, ultrasonic assistance).
• Long-term storage of prepared solutions is not advised; use freshly prepared solutions for experimental reproducibility.
• Not all anti-inflammatory effects are mediated by PPARα; off-target activities in non-PPARα-expressing systems are minimal.

Workflow Integration & Parameters

WY-14643 is supplied as a solid compound by APExBIO under SKU A4305. It is insoluble in water but dissolves in DMSO (≥16.2 mg/mL) and ethanol (≥48.8 mg/mL) with ultrasonic assistance. Store at -20°C; use prepared solutions promptly. In vitro, 250 μM is effective for endothelial studies; in vivo, 3 mg/kg/day (oral, rats, 2 weeks) or 100 mg/kg/day (IP, mice, 10 days) are established regimens. Inclusion of controls and genetic models (e.g., PparaΔHep, YapΔHep) is recommended for mechanistic validation (Wang et al., HEP-21-0169). For detailed integration strategies, see WY-14643: Selective PPARα Agonist for Metabolic Research ..., which this article extends by including best practices for dual PPARα/γ applications.

Conclusion & Outlook

WY-14643 (Pirinixic Acid) remains a gold-standard selective PPARα agonist for mechanistic and translational metabolic research. Its reproducible activity, dual PPARα/γ potential, and established in vivo efficacy enable rigorous dissection of PPAR signaling networks. Recent advances, including the elucidation of YAP-TEAD's mediating role in liver regeneration, position it as an indispensable tool for next-generation studies in metabolic, inflammatory, and regenerative biology. For detailed specifications and ordering, refer to the WY-14643 (Pirinixic Acid) product page.